pharmaphorum

OCTOBER 13, 2020

UK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen to spearhead the next stage in the company’s development into gene silencing and other areas. He said: “These big pharma companies have every type of technology available to them.

Gene Silencing 100

Gene Silencing Gene RNA Genome 100

pharmaphorum

DECEMBER 23, 2020

The results also suggest further uses for the drug in early disease and more revenues to come from one of the company’s biggest success stories from the last decade. Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition. Rare disease progress.

Marketing 96

Marketing Gene Gene Silencing Drugs 96

pharmaphorum

JANUARY 6, 2021

A host of other pharma companies including Gilead, Novo Nordisk, Merck & Co are also developing potential NASH drugs. Only this morning, Novo Nordisk selected the first candidate from a project with Dicerna to find new gene-silencing drugs to treat liver-related diseases including NASH.

Gene Silencing 52

Gene Silencing Regulation Pharma Companies Trials 52

Delveinsight

AUGUST 6, 2020

Hereditary ATTR amyloidosis , also known as Familial ATTR, is an autosomal dominant disease and a result of mutations in the TTR gene, thus it is passed down from one generation to the next one. Gene-silencing Therapies. ATTR amyloidosis can be either hereditary or acquired (non-hereditary). hATTR market : In The Pipeline.

Protein 52

Protein Gene Silencing Marketing Gene 52